NEURAL SYSTEMS, INHIBITORY CONTROL, AND METHAMPHETAMINE DEPENDENCE (IRB #05-0

神经系统、抑制控制和甲基苯丙胺依赖性 (IRB

• 批准号: 7718013
• 负责人: Edythe Danick London
• 金额: $ 24.6万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718013
• 关键词: Biological Assay; Brain; Brain region; Computer Retrieval of Information on Scientific Projects Database; Condition; Data; Dependence; Development; Disease; Drug abuse; Functional Magnetic Resonance Imaging; Funding; Grant; Institution; Knowledge; Laboratories; Maps; Measures; Methamphetamine; N-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide; Neurobiology; Performance; Pharmaceutical Preparations; Placebos; Positron-Emission Tomography; Research; Research Ethics Committees; Research Personnel; Resources; Reversal Learning; Signal Transduction; Source; Symptoms; System; Testing; Therapeutic Intervention; United States National Institutes of Health; base; dopamine D3 receptor; human subject; improved; indexing; relating to nervous system; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: This project aims to clarify the neurobiological basis for deficits in response inhibition in laboratory tests of inhibitory control in MA abusers. The objective is to map abnormalities in brain function in MA abusers, as indexed by activations measured by fMRI. PET scans, using [18F]fallypride, will be utilized to assay D2/D3 dopamine receptors in extrastriatal regions of the brain. This project also aims to test a potential medication that has shown promise in improving inhibitory control in human subjects. The knowledge gained may ultimately support evidence-based development of therapeutic interventions targeting this disease symptom in MA dependence, a drug abuse problem that has tremendous global impact. Aim 1. Identify neural substrates of inhibitory control deficits (as indicated by measures of response inhibition and ability to shift set) in MA-dependent subjects. Using data collected from the placebo condition of this study (see Aim 3), we will pair fMRI with performance on a Stop-Signal Task and a Probabilistic Reversal Learning Task in MA-dependent and control subjects.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 本项目旨在阐明在抑制控制的实验室测试中，MA滥用者反应抑制缺陷的神经生物学基础。 其目的是映射MA滥用者的脑功能异常，通过fMRI测量的激活指数。 使用[18F]fallypride的PET扫描将用于测定大脑纹状体外区域的D2/D3多巴胺受体。 该项目还旨在测试一种潜在的药物，该药物在改善人类受试者的抑制控制方面表现出了希望。 所获得的知识可能最终支持循证开发针对MA依赖中这种疾病症状的治疗干预措施，这是一个具有巨大全球影响的药物滥用问题。 目标1. 识别MA依赖受试者中抑制性控制缺陷的神经基质（如反应抑制和转移集能力的测量所示）。 使用从本研究的安慰剂条件下收集的数据（见目的3），我们将配对功能磁共振成像与性能的停止信号任务和概率记忆学习任务中的MA依赖和对照组。